title: The Effects of Armillarisin A on Serum IL-1β and IL-4 and in Treating Ulcerative Colitis.
abstract: To study the therapeutic effect of Armillarisin A on patients with ulcerative colitis (UC) and on serum IL-1β and IL-4, sixty patients with UC were randomly divided into three groups: Armillarisin A treatment group (Group I), Armillarisin-combined hormone therapy group (Group II), and hormones treatment as the control group (Group III). Patients in Group I received Armillarisin A 10 mg enema in 100 ml saline. Patients in Group II received Armillarisin A 10 mg and dexamethasone 5 mg enema in 100 ml saline. Patients in Group III received only dexamethasone 5 mg enema in 100 ml saline. The therapeutic efficacy and serum levels of IL-4 and IL-1β were observed. After 4 week treatment, the total effective rates were 90.0 % in Group I and 95.0 % in Group II. Both are higher than it in control group, which was 70.0 %. The serum levels of IL-4 in Groups I and II were significantly higher than it in control group. Compared to IL-4 levels before treatment, the levels of IL-4 after treatment were significantly higher in both Groups I and II. The serum levels of IL-11β were significantly decreased in Groups I and II in comparison to it in control group. Compared to the levels of IL-1β before treatment, the levels of IL-1β were significantly decreased. Armillarisin A shows a significant effect in treating UC. It helps increase IL-4 and lower IL-1β and the mechanism may be related to the body's immunity regulation.
authors.affiliation: Department of Gastroenterology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, Medical School of Southeast University, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, 221009, Jiangsu, China. wp71618@163.com.
authors.forename: Ping
authors.initials: P
authors.lastname: Wu
authors.affiliation: Department of Gastroenterology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, Medical School of Southeast University, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, 221009, Jiangsu, China.
authors.forename: Yonggao
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Department of Gastroenterology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, Medical School of Southeast University, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, 221009, Jiangsu, China.
authors.forename: Fangyuan
authors.initials: F
authors.lastname: Jia
authors.affiliation: Department of Gastroenterology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, Medical School of Southeast University, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, 221009, Jiangsu, China.
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000097:blood* / Q000188:drug therapy*; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007107:Immune System; D053583:Interleukin-1beta / Q000097:blood*; D015847:Interleukin-4 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001578:Benzopyrans; C508585:IL1B protein, human; C508598:IL4 protein, human; D053583:Interleukin-1beta; D015847:Interleukin-4; D003907:Dexamethasone; C023435:armillarisin A
keywords: Armillarisin; IL-1β; IL-4; Ulcerative colitis